2023-03-28 09:12:37 ET
- InMed Pharma ( NASDAQ: INM ) said it had completed enrollment for its Phase 2 trial testing investigational drug, INM-755, a cannabinol cream to treat epidermolysis bullosa (EB), a rare genetic skin disease.
- The company said results from the Phase 2 study of the cream were expected to be released on early Q3.
- The trial will test the safety and efficacy in treating symptoms of itch, pain, and wound healing in patients with epidermolysis bullosa .
For further details see:
InMed completes enrollment to test cannabinol cream to treat epidermolysis bullosa, results from trial in early Q3